Protagonist Therapeutics, Inc.
14
1
3
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
7.1%
1 terminated/withdrawn out of 14 trials
90.9%
+4.4% vs industry average
14%
2 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (14)
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PN-881 in Healthy Subjects.
Role: lead
Safety and Efficacy Study of PTG-100 in the Treatment of Moderate to Severe Ulcerative Colitis
Role: lead
PTG-300 in Subjects With Hereditary Hemochromatosis
Role: lead
A Phase 3 Study of Rusfertide in Patients With Polycythemia Vera
Role: lead
Hepcidin Mimetic in Patients With Polycythemia Vera (REVIVE)
Role: lead
Study to Evaluate the Long-term Safety of Rusfertide (PTG-300) in Subjects With Polycythemia Vera
Role: lead
PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Role: lead
PN-943 in Adults With Moderate to Severe Active Ulcerative Colitis (UC)
Role: lead
Pharmacokinetics of PN-232 in Healthy Volunteers
Role: lead
PTG-100 for Patients With Celiac Disease
Role: collaborator
Pharmacokinetics of PN-235 in Healthy Volunteers
Role: lead
Pharmacokinetics and Pharmacodynamics of Different PTG-300 Regimens in Healthy Volunteers
Role: lead
Safety Study for Beta Thalassemia Subjects on PTG-300
Role: lead
Study of PTG-300 in Non-Transfusion Dependent and Transfusion-Dependent Beta-Thalassemia Subjects With Chronic Anemia
Role: lead
All 14 trials loaded